381 related articles for article (PubMed ID: 28581126)
1. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
3. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
4. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of head and neck squamous cell carcinoma.
Pan Q; Gorin MA; Teknos TN
Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
7. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
8. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
Murdoch D
Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
[TBL] [Abstract][Full Text] [Related]
9. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Muratori L; La Salvia A; Sperone P; Di Maio M
Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
[TBL] [Abstract][Full Text] [Related]
10. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
11. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence.
Benson R; Mallick S; Julka PK; Rath GK
J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
Bernier J; Vrieling C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
[TBL] [Abstract][Full Text] [Related]
13. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for head and neck cancer.
Wen Y; Grandis JR
Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
[TBL] [Abstract][Full Text] [Related]
18. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
Martinez-Useros J; Garcia-Foncillas J
Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
20. Emerging molecular targeted therapies in the treatment of head and neck cancer.
Bozec A; Peyrade F; Fischel JL; Milano G
Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
